- Home
- INVH vs IKT Comparison
INVH vs IKT Comparison
Compare INVH & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INVH | IKT |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 240.1M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INVH | IKT |
|---|---|---|
| Price | $25.59 | $1.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $32.44 | $5.00 |
| AVG Volume (30 Days) | ★ 6.7M | 1.3M |
| Earning Date | 04-29-2026 | 03-26-2026 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | 29.73 | ★ 57.76 |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $2,729,296,000.00 | N/A |
| Revenue This Year | $3.21 | N/A |
| Revenue Next Year | $2.64 | $33.33 |
| P/E Ratio | $25.93 | ★ N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $24.25 | $1.33 |
| 52 Week High | $35.80 | $2.37 |
Technical Indicators
Market Signals| Indicator | INVH | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 47.70 |
| Support Level | $25.37 | $1.43 |
| Resistance Level | $27.65 | $1.88 |
| Average True Range (ATR) | 0.50 | 0.12 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 91.79 | 35.29 |
Price Performance
Historical ComparisonAbout INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with over 70% of the portfolio in the Western US and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.